

Health Research and Development Expenditures by Therapeutic Class, 2008

Si vous préférez ce questionnaire en français, veuillez nous appeler au 1-866-824-5893

Reporting organization name and address

Correct as required

0101 Company name

0102 Date and reason for name change

0103 C/O

0104 Address

0105 City

0106 Province/Territory 0107 Postal code

Please correct any mistake in name or address

INFORMATION FOR RESPONDENTS

Survey objective

This survey collects data which are essential to plan and evaluate research and development programs. Data will be used by the Applied Research and Analysis Directorate (ARAD) of Health Canada to monitor and support the development of science and technology policy.

Autorisation

This survey is conducted under the authority of the *Statistics Act*, Revised Statutes of Canada, 1985, Chapter S19. Completion of this questionnaire is a legal requirement under the *Statistics Act*. Your participation is appreciated.

Confidentiality

The *Statistics Act* protects the confidentiality of information collected by Statistics Canada. Statistics Canada is prohibited by law from releasing any information from this survey which would identify a person, business, or organization, without their prior consent. The confidentiality provisions of the *Statistics Act* are not affected by either the *Access to Information Act* or any other legislation. Therefore, for example, the Canada Revenue Agency cannot access identifiable survey data from Statistics Canada.

These survey data will only be used for statistical purposes and will be published in an aggregate form only.

Data-Sharing Agreements

In order to avoid duplication of enquiry, to reduce the cost of data collection and to provide consistent statistics, Statistics Canada has entered into agreements with:

- the Institut de la statistique du Québec (ISQ), under Section 11 of the *Statistics Act*, where data on firms located or having research

and development (R&D) activities in Quebec will be transmitted to the ISQ. The *Act respecting the Institut de la statistique du Québec* includes the same provisions for confidentiality and penalties for disclosure of information as the federal *Statistics Act*.

- the ARAD, under Section 12 of the *Statistics Act*, for the joint collection and sharing of information. The ARAD shall keep the information confidential and use it for statistical purposes only. Under Section 12, you may refuse to share your information with the ARAD by writing a letter of objection to the Chief Statistician of Canada and returning it with your completed questionnaire.

Reporting period and coverage

This questionnaire should be completed for the **fiscal year ending in 2008**. This report should exclude foreign operations. Please report all amounts in **Canadian currency**.

Note: Total R&D reported on page 5 should equal the 2008 total expenditures reported on line 605 of your T661 form "Claim for Scientific Research and Experimental Development (SRED) carried out in Canada."

The first level classes of the Anatomical Therapeutic Chemical (ATC) system are used in this questionnaire. Some basic information about this system is provided in Appendix A.

Planned data linkage

To enhance the data from this survey, Statistics Canada intends to combine the information from the Health R&D Expenditures by Therapeutic Class Survey with the information your organization provided on the Research and Development in Canadian Industry Survey, if applicable.

Fiscal year ending in 2008

From: 00001 Year Month Day To: 00002 Year Month Day

2 0 0 2 0 0 8

Please return the completed questionnaire within 30 days of receipt.

If you are unable to do so, please inform us of the expected completion date. If you receive more than one copy of this survey questionnaire for the same business, please complete one and attach and return the duplicate(s). If you require assistance in the completion of this questionnaire or have any questions regarding the survey please address all enquiries to:

Science and Technology Surveys Section
 Science, Innovation and Electronic Information Division
 Statistics Canada

Ottawa, Ontario K1A 0T6
 E-mail: sieidinfo@statcan.gc.ca
 Fax: (613) 951-9920

1. Is your organization: Please check appropriate category.

- 00003 a brand name pharmaceutical company a contract research organization (CRO)
 a generic pharmaceutical company a biotechnology or biopharmaceutical company
 Other (please specify) 00016

2. Did your organization perform any R&D related to the discovery and/or development of therapeutic products for human use in 2008?

- 00004 Yes ▶ Please go to Question 3
 No ▶ Please complete certification on page 6 and return this questionnaire in the prepaid envelope. Thank you for your cooperation.

3. For each therapeutic class listed below, please indicate, by stage of development, the number of R&D projects performed by your organization in 2008 and their related expenditures, for new* product development and for existing* product improvements. Please report R&D performed in Canada only.

In cases where no R&D was performed, please check "No" and move to the next class.

1. Alimentary Tract and Metabolism.

- 1001 No ▶ Move to next class
 Yes →

	R&D expenditures in 2008 1002 <input type="text"/> (\$000)				Number of R&D targets* 1003 <input type="text"/> #			
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*	
a) Number of R&D projects for new product development	1010 #	1020 #	1030 #	1040 #	1050 #	1060 #	1070 #	
b) R&D expenditures in 2008 for new product development	1011 (\$000)	1021 (\$000)	1031 (\$000)	1041 (\$000)	1051 (\$000)	1061 (\$000)	1071 (\$000)	
c) Number of R&D projects for existing product improvements	1012 #	1022 #	1032 #	1042 #	1052 #	1062 #	1072 #	
d) R&D expenditures in 2008 for existing product improvements	1013 (\$000)	1023 (\$000)	1033 (\$000)	1043 (\$000)	1053 (\$000)	1063 (\$000)	1073 (\$000)	

2. Blood and Blood Forming Organs.

- 2001 No ▶ Move to next class
 Yes →

	R&D expenditures in 2008 2002 <input type="text"/> (\$000)				Number of R&D targets* 2003 <input type="text"/> #			
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*	
a) Number of R&D projects for new product development	2010 #	2020 #	2030 #	2040 #	2050 #	2060 #	2070 #	
b) R&D expenditures in 2008 for new product development	2011 (\$000)	2021 (\$000)	2031 (\$000)	2041 (\$000)	2051 (\$000)	2061 (\$000)	2071 (\$000)	
c) Number of R&D projects for existing product improvements	2012 #	2022 #	2032 #	2042 #	2052 #	2062 #	2072 #	
d) R&D expenditures in 2008 for existing product improvements	2013 (\$000)	2023 (\$000)	2033 (\$000)	2043 (\$000)	2053 (\$000)	2063 (\$000)	2073 (\$000)	

3. Cardiovascular System.

- 3001 No ▶ Move to next class
 Yes →

	R&D expenditures in 2008 3002 <input type="text"/> (\$000)				Number of R&D targets* 3003 <input type="text"/> #			
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*	
a) Number of R&D projects for new product development	3010 #	3020 #	3030 #	3040 #	3050 #	3060 #	3070 #	
b) R&D expenditures in 2008 for new product development	3011 (\$000)	3021 (\$000)	3031 (\$000)	3041 (\$000)	3051 (\$000)	3061 (\$000)	3071 (\$000)	
c) Number of R&D projects for existing product improvements	3012 #	3022 #	3032 #	3042 #	3052 #	3062 #	3072 #	
d) R&D expenditures in 2008 for existing product improvements	3013 (\$000)	3023 (\$000)	3033 (\$000)	3043 (\$000)	3053 (\$000)	3063 (\$000)	3073 (\$000)	

* see definitions in Appendix A

4. Dermatologicals.

4001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008						4002 (\$000)		Number of R&D targets*		4003 #	
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*					
a) Number of R&D projects for new product development	4010 #	4020 #	4030 #	4040 #	4050 #	4060 #	4070 #					
b) R&D expenditures in 2008 for new product development	4011 (\$000)	4021 (\$000)	4031 (\$000)	4041 (\$000)	4051 (\$000)	4061 (\$000)	4071 (\$000)					
c) Number of R&D projects for existing product improvements	4012 #	4022 #	4032 #	4042 #	4052 #	4062 #	4072 #					
d) R&D expenditures in 2008 for existing product improvements	4013 (\$000)	4023 (\$000)	4033 (\$000)	4043 (\$000)	4053 (\$000)	4063 (\$000)	4073 (\$000)					

5. Genito-urinary Systems and Sex Hormones.

5001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008						5002 (\$000)		Number of R&D targets*		5003 #	
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*					
a) Number of R&D projects for new product development	5010 #	5020 #	5030 #	5040 #	5050 #	5060 #	5070 #					
b) R&D expenditures in 2008 for new product development	5011 (\$000)	5021 (\$000)	5031 (\$000)	5041 (\$000)	5051 (\$000)	5061 (\$000)	5071 (\$000)					
c) Number of R&D projects for existing product improvements	5012 #	5022 #	5032 #	5042 #	5052 #	5062 #	5072 #					
d) R&D expenditures in 2008 for existing product improvements	5013 (\$000)	5023 (\$000)	5033 (\$000)	5043 (\$000)	5053 (\$000)	5063 (\$000)	5073 (\$000)					

6. Systemic Hormonal Preparation excluding Sex Hormones and Insulin.

6001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008						6002 (\$000)		Number of R&D targets*		6003 #	
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*					
a) Number of R&D projects for new product development	6010 #	6020 #	6030 #	6040 #	6050 #	6060 #	6070 #					
b) R&D expenditures in 2008 for new product development	6011 (\$000)	6021 (\$000)	6031 (\$000)	6041 (\$000)	6051 (\$000)	6061 (\$000)	6071 (\$000)					
c) Number of R&D projects for existing product improvements	6012 #	6022 #	6032 #	6042 #	6052 #	6062 #	6072 #					
d) R&D expenditures in 2008 for existing product improvements	6013 (\$000)	6023 (\$000)	6033 (\$000)	6043 (\$000)	6053 (\$000)	6063 (\$000)	6073 (\$000)					

7. Anti-infectives for Systemic Use.

7001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008						7002 (\$000)		Number of R&D targets*		7003 #	
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*					
a) Number of R&D projects for new product development	7010 #	7020 #	7030 #	7040 #	7050 #	7060 #	7070 #					
b) R&D expenditures in 2008 for new product development	7011 (\$000)	7021 (\$000)	7031 (\$000)	7041 (\$000)	7051 (\$000)	7061 (\$000)	7071 (\$000)					
c) Number of R&D projects for existing product improvements	7012 #	7022 #	7032 #	7042 #	7052 #	7062 #	7072 #					
d) R&D expenditures in 2008 for existing product improvements	7013 (\$000)	7023 (\$000)	7033 (\$000)	7043 (\$000)	7053 (\$000)	7063 (\$000)	7073 (\$000)					

* see definitions in Appendix A

8. Antineoplastic and Immunomodulating Agents.

8001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008						8002 (\$000)		Number of R&D targets*		8003 #	
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*					
a) Number of R&D projects for new product development	8010 #	8020 #	8030 #	8040 #	8050 #	8060 #	8070 #					
b) R&D expenditures in 2008 for new product development	8011 (\$000)	8021 (\$000)	8031 (\$000)	8041 (\$000)	8051 (\$000)	8061 (\$000)	8071 (\$000)					
c) Number of R&D projects for existing product improvements	8012 #	8022 #	8032 #	8042 #	8052 #	8062 #	8072 #					
d) R&D expenditures in 2008 for existing product improvements	8013 (\$000)	8023 (\$000)	8033 (\$000)	8043 (\$000)	8053 (\$000)	8063 (\$000)	8073 (\$000)					

9. Musculo-skeletal Systems.

9001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008						9002 (\$000)		Number of R&D targets*		9003 #	
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*					
a) Number of R&D projects for new product development	9010 #	9020 #	9030 #	9040 #	9050 #	9060 #	9070 #					
b) R&D expenditures in 2008 for new product development	9011 (\$000)	9021 (\$000)	9031 (\$000)	9041 (\$000)	9051 (\$000)	9061 (\$000)	9071 (\$000)					
c) Number of R&D projects for existing product improvements	9012 #	9022 #	9032 #	9042 #	9052 #	9062 #	9072 #					
d) R&D expenditures in 2008 for existing product improvements	9013 (\$000)	9023 (\$000)	9033 (\$000)	9043 (\$000)	9053 (\$000)	9063 (\$000)	9073 (\$000)					

10. Nervous System.

10001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008						10002 (\$000)		Number of R&D targets*		10003 #	
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*					
a) Number of R&D projects for new product development	10010 #	10020 #	10030 #	10040 #	10050 #	10060 #	10070 #					
b) R&D expenditures in 2008 for new product development	10011 (\$000)	10021 (\$000)	10031 (\$000)	10041 (\$000)	10051 (\$000)	10061 (\$000)	10071 (\$000)					
c) Number of R&D projects for existing product improvements	10012 #	10022 #	10032 #	10042 #	10052 #	10062 #	10072 #					
d) R&D expenditures in 2008 for existing product improvements	10013 (\$000)	10023 (\$000)	10033 (\$000)	10043 (\$000)	10053 (\$000)	10063 (\$000)	10073 (\$000)					

11. Antiparasitic Products, Insecticides and Repellents.

11001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008						11002 (\$000)		Number of R&D targets*		11003 #	
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*					
a) Number of R&D projects for new product development	11010 #	11020 #	11030 #	11040 #	11050 #	11060 #	11070 #					
b) R&D expenditures in 2008 for new product development	11011 (\$000)	11021 (\$000)	11031 (\$000)	11041 (\$000)	11051 (\$000)	11061 (\$000)	11071 (\$000)					
c) Number of R&D projects for existing product improvements	11012 #	11022 #	11032 #	11042 #	11052 #	11062 #	11072 #					
d) R&D expenditures in 2008 for existing product improvements	11013 (\$000)	11023 (\$000)	11033 (\$000)	11043 (\$000)	11053 (\$000)	11063 (\$000)	11073 (\$000)					

* see definitions in Appendix A

12. Respiratory System.

12001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008 <input type="text" value="12002"/> (\$000)						Number of R&D targets* <input type="text" value="12003"/> #		
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*		
a) Number of R&D projects for new product development	12010 #	12020 #	12030 #	12040 #	12050 #	12060 #	12070 #		
b) R&D expenditures in 2008 for new product development	12011 (\$000)	12021 (\$000)	12031 (\$000)	12041 (\$000)	12051 (\$000)	12061 (\$000)	12071 (\$000)		
c) Number of R&D projects for existing product improvements	12012 #	12022 #	12032 #	12042 #	12052 #	12062 #	12072 #		
d) R&D expenditures in 2008 for existing product improvements	12013 (\$000)	12023 (\$000)	12033 (\$000)	12043 (\$000)	12053 (\$000)	12063 (\$000)	12073 (\$000)		

13. Sensory Organs.

13001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008 <input type="text" value="13002"/> (\$000)						Number of R&D targets* <input type="text" value="13003"/> #		
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*		
a) Number of R&D projects for new product development	13010 #	13020 #	13030 #	13040 #	13050 #	13060 #	13070 #		
b) R&D expenditures in 2008 for new product development	13011 (\$000)	13021 (\$000)	13031 (\$000)	13041 (\$000)	13051 (\$000)	13061 (\$000)	13071 (\$000)		
c) Number of R&D projects for existing product improvements	13012 #	13022 #	13032 #	13042 #	13052 #	13062 #	13072 #		
d) R&D expenditures in 2008 for existing product improvements	13013 (\$000)	13023 (\$000)	13033 (\$000)	13043 (\$000)	13053 (\$000)	13063 (\$000)	13073 (\$000)		

14. Various Others (please specify)

14001 No **▶ Move to next class**

Yes **→**

	R&D expenditures in 2008 <input type="text" value="14002"/> (\$000)						Number of R&D targets* <input type="text" value="14003"/> #		
	Discovery R&D	Pre-clinical Trials*	Phase I Trials	Phase II Trials	Phase III Trials*	Pending Approval	Approved*		
a) Number of R&D projects for new product development	14010 #	14020 #	14030 #	14040 #	14050 #	14060 #	14070 #		
b) R&D expenditures in 2008 for new product development	14011 (\$000)	14021 (\$000)	14031 (\$000)	14041 (\$000)	14051 (\$000)	14061 (\$000)	14071 (\$000)		
c) Number of R&D projects for existing product improvements	14012 #	14022 #	14032 #	14042 #	14052 #	14062 #	14072 #		
d) R&D expenditures in 2008 for existing product improvements	14013 (\$000)	14023 (\$000)	14033 (\$000)	14043 (\$000)	14053 (\$000)	14063 (\$000)	14073 (\$000)		

TOTAL

Total Health R&D (sum of 1 – 14).....	<input type="text" value="15002"/>	<input type="text" value="(\$000)"/>
Other R&D in 2008	<input type="text" value="15004"/>	<input type="text" value="(\$000)"/>
Total R&D in 2008 ¹	<input type="text" value="15005"/>	<input type="text" value="(\$000)"/>
Planned Health R&D for 2009	<input type="text" value="15006"/>	<input type="text" value="(\$000)"/>
Forecast Health R&D for 2010.....	<input type="text" value="15007"/>	<input type="text" value="(\$000)"/>

Total number of R&D targets	<input type="text" value="15003"/>	<input type="text" value="#"/>
-----------------------------------	------------------------------------	--------------------------------

If your total R&D in 2008 (line 5005) includes payments made to other institutions/organizations such as hospitals or universities, please indicate the amount of these payments.....

1. Should equal the 2008 total expenditures reported on line 605 of your T661 form "Claim for Scientific Research and Experimental Development (SR&ED) Expenditures" carried on in Canada.

* see definitions in Appendix A

CERTIFICATION

Please complete **certification** below and return this questionnaire in the prepaid envelope.
Thank you for your cooperation.

Name of person who completed this report (please print) 00005	Business address 00006	Date 00008 YY MM DD	
Official position 00007	Postal code 00009	Telephone number 00010 - -	Ext. 00011
E-mail address 00012	GST number (BN number) 00013	Fax number 00014 - -	

SURVEY COMPLETION TIME

Please indicate how long it took you to complete this questionnaire.

00015 minutes

The results of this survey will be published in
"Industrial Research and Development" (Cat. No. 88-202-XIE)
<http://www.statcan.gc.ca/cgi-bin/downpub/freepub.cgi?subject=193#193>

THANK YOU FOR YOUR CO-OPERATION

COMMENTS

APPENDIX A

Targets – R&D targets refers to the number of end-products that are hoped to evolve from the current research being performed.

New product development – please consider new to mean totally or essentially new/unknown to the personnel of your organization.

Existing product improvement – please consider existing to mean that personnel of your organization would be improving a product or process about which they have at least basic information.

Pre-clinical trials – includes toxicology testing.

Phase III trials – please include phase IIIB bioequivalence testing and all other testing before submitting for approval.

Approved – please include phase IV trials and other testing in comparison with other competing products on the market.

The ATC classification – structure and principles

The Anatomical Therapeutic Chemical (ATC) system is recognized by the World Health Organization (WHO) as an international standard for drug utilization studies. The purpose of the ATC system is to serve as a tool for drug utilization research in order to improve quality of drug use. ATC codes are maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway.

In the ATC classification system, the drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutic properties. Drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with one pharmacological/therapeutic subgroup (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups.

Medicinal products are classified according to the main therapeutic use of the main active ingredient, on the basic principle of only one ATC code for each pharmaceutical formulation (i.e. similar ingredients, strength and pharmaceutical form). A medicinal product can be given more than one ATC code if it is available in two or more strengths or formulations with clearly different therapeutic uses.

ATC pharmacological / therapeutic 1st level groups and 2nd level subgroups

1. Alimentary Tract and Metabolism

A01	Stomatological Preparations
A02	Drugs For Acid Related Disorders
A03	Drugs For Functional Gastrointestinal Disorders
A04	Antiemetics And Antinauseants
A05	Bile And Liver Therapy
A06	Laxatives
A07	Antidiarrheals, Intestinal Antiinflammatory/ Antiinfective Agents
A08	Antiobesity Preparations, Excl. Diet Products
A09	Digestives, Incl. Enzymes
A10	Drugs Used In Diabetes
A11	Vitamins
A12	Mineral Supplements
A13	Tonics
A14	Anabolic Agents For Systemic Use
A15	Appetite Stimulants
A16	Other Alimentary Tract And Metabolism Products

2. Blood and Blood Forming Organs

B05	Blood Substitutes And Perfusion Solutions
A10B	Oral Blood Glucose Lowering Drugs
B05A	Blood And Related Products
A10Bx	Other Oral Blood Glucose Lowering Drugs
B02Bd	Blood Coagulation Factors
B05Aa	Blood Substitutes And Plasma Protein Fractions
V07Ac	Blood Transfusion, Auxiliary Products
V07Ad	Blood Tests, Auxiliary Products
B05Aa03	Fluorocarbon Blood Substitutes

3. Cardiovascular System

C01	Cardiac Therapy
C02	Antihypertensives
C03	Diuretics
C04	Peripheral Vasodilators
C05	Vasoprotectives
C07	Beta Blocking Agents
C08	Calcium Channel Blockers
C09	Agents Acting On The Renin-Angiotensin System
C10	Serum Lipid Reducing Agents

4. Dermatologicals

D01	Antifungals For Dermatological Use
D02	Emollients And Protectives
D03	Preparations For Treatment Of Wounds And Ulcers
D04	Antipruritics, Incl. Antihistamines, Anesthetics, Etc.
D05	Antipsoriatics
D06	Antibiotics And Chemotherapeutics For Dermatological Use
D07	Corticosteroids, Dermatological Preparations
D08	Antiseptics And Disinfectants
D09	Medicated Dressings
D10	Anti-Acne Preparations
D11	Other Dermatological Preparations

Continued on page 8

5. Genito Urinary System and Sex Hormones

- G01 Gynecological Antiinfectives And Antiseptics
- G02 Other Gynecologicals
- G03 Sex Hormones And Modulators Of The Genital System
- G04 Urologicals

6. Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins

- H01 Pituitary And Hypothalamic Hormones and Analogues
- H02 Corticosteroids For Systemic Use
- H03 Thyroid Therapy
- H04 Pancreatic Hormones
- H05 Calcium Homeostasis

7. Antiinfectives For Systemic Use

- J01 Antibacterials For Systemic Use
- J02 Antimycotics For Systemic Use
- J04 Antimycobacterials
- J05 Antivirals For Systemic Use
- J06 Immune Sera And Immunoglobulins
- J07 Vaccines

8. Antineoplastic and Immunomodulating Agents

- L01 Antineoplastic Agents
- L02 Endocrine Therapy
- L03 Immunostimulants
- L04 Immunosuppressive Agents

9. Musculo-Skeletal System

- M01 Antiinflammatory And Antirheumatic Products
- M02 Topical Products For Joint And Muscular Pain
- M03 Muscle Relaxants
- M04 Antigout Preparations
- M05 Drugs For Treatment Of Bone Diseases
- M09 Other Drugs For Disorders Of The Musculo-Skeletal System

10. Nervous System

- N01 Anesthetics
- N02 Analgesics
- N03 Antiepileptics
- N04 Anti-Parkinson Drugs
- N05 Psycholeptics
- N06 Psychoanaleptics
- N07 Other Nervous System Drugs

11. Antiparasitic Products, Insecticides and Repellents

- P01 Antiprotozoals
- P02 Anthelmintics
- P03 Ectoparasiticides, Incl. Scabicides, Insecticides And Repellents

12. Respiratory System

- R01 Nasal Preparations
- R02 Throat Preparations
- R03 Drugs For Obstructive Airway Diseases
- R05 Cough And Cold Preparations
- R06 Antihistamines For Systemic Use
- R07 Other Respiratory System Products

13. Sensory Organs

- S01 Ophthalmologicals
- S02 Otologicals
- S03 Ophthalmological And Otological Preparations

14. Various Others

- V01 Allergens
- V03 All Other Therapeutic Products
- V04 Diagnostic Agents
- V06 General Nutrients
- V07 All Other Non-Therapeutic Products
- V08 Contrast Media
- V09 Diagnostic Radiopharmaceuticals
- V10 Therapeutic Radiopharmaceuticals
- V20 Surgical Dressings